Modern reirradiation for recurrent gliomas can safely delay tumor progression

Ryan S. Youland, John Y. Lee, Cole R. Kreofsky, Paul D. Brown, Joon H. Uhm, Nadia N. Laack

Research output: Contribution to journalArticlepeer-review

1 Scopus citations


Background: Despite advances in modern therapy, high-grade gliomas continue to portend a dismal prognosis and nearly all patients will experience relapse. Unfortunately, salvage options remain limited. In this study, we assessed outcomes for patients with recurrent gliomas treated with reirradiation. Methods: We retrospectively identified 48 glioma patients treated with reirradiation between 2013 and 2016. All had radiographic or pathologic evidence of recurrence. Prognostic factors were abstracted from the electronic medical record. Results: Initial surgery included biopsy in 15, subtotal resection in 21, and gross total resection in 12. Initial chemotherapy included temozolomide (TMZ) in 31, TMZ+dasatinib in 7, TMZ+vorinostat in 3, and procarbazine, lomustine, and vincristine in 2. The median dose of primary radiotherapy was 60 Gy delivered in 30 fractions. Median overall survival (OS) and progression-free survival (PFS) from initial diagnosis were 3.2 and 1.7 years, respectively. A total of 36 patients failed salvage bevacizumab before reirradiation. Salvage surgery was performed before reirradiation in 21 patients. Median time to reirradiation was 1.7 years. Median follow-up was 13.7 months from reirradiation. Concurrent systemic therapy was given in 33 patients (bevacizumab in 27, TMZ in 8, and lomustine in 2). Median PFS and OS after reirradiation were 3.2 and 6.3 months, respectively. Radionecrosis occurred in 4 patients and no radionecrosis was seen in patients receiving concurrent bevacizumab with reirradiation (0% vs 19%, P = .03). Conclusions: Reirradiation may result in delayed tumor progression with acceptable toxicity. Prospective trials are needed to determine the impact of reirradiation on tumor progression and quality of life.

Original languageEnglish (US)
Pages (from-to)46-55
Number of pages10
JournalNeuro-Oncology Practice
Issue number1
StatePublished - Mar 2 2018


  • Glioblastoma
  • Glioma
  • Radionecrosis
  • Recurrence
  • Reirradiation

ASJC Scopus subject areas

  • Medicine (miscellaneous)


Dive into the research topics of 'Modern reirradiation for recurrent gliomas can safely delay tumor progression'. Together they form a unique fingerprint.

Cite this